Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovoSeven Wins Expanded Indication For Acquired Hemophilia

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.

You may also be interested in...



Novo Drops NovoSeven Stroke Program Following Phase III Failure

Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.

Novo Drops NovoSeven Stroke Program Following Phase III Failure

Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.

FDA Should Relax Endpoint Requirements For Emergency Research, Novo Nordisk Says

“Reduction of substantial morbidity alone should be sufficient” benefit in medical trials conducted under emergency conditions, the firm says.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel